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        Imputed microRNA regulation based on weighted ranked expression and putative 
microRNA targets (IMRE) is a method to predict microRNA regulation from genome-wide gene 
expression. A false discovery rate (FDR) for each microRNA is calculated using the expression 
of the microRNA putative targets to analyze the regulation between different conditions. FDR is 
calculated to identify the differences of gene expression. The dataset used in this research is the 
microarray gene expression of 596 patients with prostate cancer. This dataset includes three 
different phenotypes: PSA (Prostate-Specific Antigen recurrence), Systemic (Systemic Disease 
Progression) and NED (No Evidence of Disease). We used the IMRE and ANOVA methods to 
analyze the dataset and identified several microRNA candidates that can be used to predict PSA 
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CHAPTER 1. INTRODUCTION 
        A microRNA (abbreviated miRNA) is a small non-protein-coding RNA molecule 
(containing about 22 nucleotides) found in plants, animals, and some viruses, which functions in 
transcriptional and post-transcriptional regulation of gene expression (Chen & Rajewsky, 2007). 
In animals, about 1–5% of the predicted genes encode miRNAs, and these miRNAs can regulate 
about 60% of the protein-coding genes (Kusenda et al, 2006). So far, there are 24,521 miRNAs 
in the miRBase database, which is a searchable database of published miRNA sequences and 
annotation (Griffiths-Jones, 2004). Each of the miRNA is believed to regulate multiple genes by 
specific inhibition of translation or induction of mRNA cleavage. Thus it is important to study 
miRNAs and their predicted targets to have a better understanding in developmental and 
physiological processes, such as cell differentiation, metabolic pathway, and genetic regulations. 
        Recent research of miRNAs and their targets indicated that they might play an important 
role in several human diseases. For instance, changes in expression levels of specific miRNAs in 
diseased human hearts might evoke cardiac hypertrophy and heart failure (van Rooij et al, 2011). 
Recent studies show that miR–204 can work as the tumor suppressor to suppress head and neck 
tumor metastasis (Lee et al, 2011). Therefore, miRNA analysis is a good method to understand 
the mechanism of some diseases and it is possible to find some effective cures for these diseases. 
        The study of prostate cancer has become one of the hottest fields in recent years. Prostate 
cancer is the most common non-skin cancer among men worldwide (Parkin et al, 2001) and it is 
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also the second leading cause of death due to cancer after lung cancer among men in the United 
States (Jemal et al, 2010). Currently prostate specific antigen (PSA) is the key diagnostic 
standard to detect prostate cancer. However, PSA has two properties: variability and limited 
specificity to cancer, which lead to limited utility in prostate cancer screening and 
characterization (Martin et al, 2012). Hence, it is necessary to search for new biomarkers to 
allow for the prediction of prostate cancer and its recurrence. 
        In this study, the IMRE method and the Analysis of variance (ANOVA) method will be used 
to analyze the gene expression data set of prostate cancer and predict the possible miRNA 
candidates which might regulate PSA recurrence and systemic disease progression in prostate 
cancer patients. The false discovery rate (FDR) will be controlled at the nominal 0.05 level to 
adjust for multiple comparisons (Benjamini, 1995). The results from both methods will be 






CHAPTER 2. METHOLOGY 
        In this study, two methods are used to predict miRNA regulation based on microarray data: 
Imputed microRNA regulation based on weighted ranked expression and putative microRNA 
targets (IMRE) and analysis of variance (ANOVA). A p-value is calculated in each method and 
the false discovery rate (FDR) analysis is conducted to control multiple comparisons.  
2.1.  IMRE 
        IMRE is a method to predict miRNA regulation using genome–wide gene expression 
information and miRNA putative targets predicted by the miRNome database (Lee et al, 2011). A 
weighted ranked exponential score is calculated for each miRNA of each sample. The student’s 
t–test is conducted to check the difference among conditions. The false discovery rate (FDR) was 
estimated based on the p-values from the t–test to adjust for multiple comparisons (Benjamini, 
1995). It is used to control the proportion of the false discoveries, which are the incorrectly 
rejected null hypotheses in the studies where the null-hypotheses are rejected. The false 
discovery rate is a less stringent condition than the family-wise error rate, so these methods are 
more powerful than the others. 
2.1.1.  Expression processing 
     Assume a data set, generated from a microarray experiment, contains X samples with  
expression from G genes in each sample. The samples are devided into a groups/phenotypes. 
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        The first step for the IMRE method is to process the expression data and calculate the 
exponential weighted score for each gene with respect to each sample. The exponential weighted 
score (𝑆𝑥,𝑗) for gene x with respect to sample j is calculated using the formula below: 
𝑆𝑥,𝑗 = (𝑟𝑥,𝑗) × (𝑒
𝑟𝑥,𝑗
𝐺 ) 
where 𝑟𝑥,𝑗 is the rank of the expression level of x
th gene among all genes in sample j, which 
𝑟𝑥,𝑗 ∈ {1, 2…𝐺}. G is the total number of genes in the j
th sample.  
2.1.2.  Prediction of miRNA target regulation 
        The second step is to predict the miRNA target regulation based on the exponential 
weighted scores calculated in the previous step. For the ith miRNA mi, the differences of the 
mean scores between the targets of miRNA (𝑚𝑖) and non–targets of miRNA (𝑚𝑖), referred as to 
△ 𝐶𝑊𝑅𝐸𝑖, is used to determine the expression level difference between the targets and non–targets 








∑ (𝑆𝑥,𝑗)𝑥∈𝑁𝑖,𝑗 , 
△ 𝐶𝑊𝑅𝐸𝑖 = 𝐶𝑇𝑖,𝑗 − 𝐶𝑁𝑖,𝑗, 
where |𝑇𝑖,𝑗| is the cardinality (count of genes) of the target gene set of microRNA (𝑚𝑖) and  
|𝑁𝑖,𝑗| is the cardinality (count of genes) of the non-target gene set of microRNA (𝑚𝑖); 𝐶𝑇𝑖,𝑗 is the 
mean score of the targets of microRNA (𝑚𝑖) and 𝐶𝑁𝑖,𝑗 is the mean score of the non–targets of 
microRNA (𝑚𝑖). Prediction of microRNAs deregulated in cancer from enrichment analysis of 
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inheritable cancer genes is performed on the miRNA–target relationships found in the Online 
Mendelian Inheritance in Man (OMIM). OMIM is a comprehensive database of human genes 
and genetic phenotypes, which provides references and supports for human genetics research and 
disease study (Hamosh et al, 1995). It includes 610 inheritance cancer genes and 586 (96%) of 
these genes are predicted targets of 527 miRNAs in the miRNome database, which can be used 
to calculate the significantly enriched miRNAs (Lee et al, 2011). 
The cumulative hypergeometric distribution was applied to calculate the p-values from the 
t-test to identify significantly enriched microRNAs. The formula is as follow:  












where N is the number of genes in both OMIM and miRNome (3232 for anatomy, 2181 for 
disease), M is the number of genes associated with a specific cancer in OMIM as well as any 
predicted target of miRNA in miRNome, n is the number of genes targeted by any miRNA in 
miRNome and also associated to a specific cancer in OMIM, m is the number of genes 
associated to both specific cancer in OMIM and certain miRNA in miRNome (Lee et al, 2011). 
Here, m = M∩n. 
        The false discovery rate (FDR) is calculated for multiple comparisons using the formula 
below: 
p′ = 1 − (1 − p)𝑛 
where n is the number of comparisons. 
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2.2.  ANOVA 
        ANOVA is a statistical method used to analyze the differences between group means, which 
was developed by Ronald A. Fisher. It tests if the means of several groups are equal. Several 
assumptions should be held: 
 a). The observations should be independent with each other; 
 b). The observations should follow normal distributions; 
 c). The variances of observations in groups should be the same; 
 d). The error terms are independently, identically, and normally distributed. 
        For each gene, a p-value is calculated using the ANOVA method. The same FDR is used to 
control the p-values for multiple testings. 
        The normality assumption is checked using the quantile–quantile plots (Q–Q plot) and 
normal probably plots. Levene’s test is conducted to check the homoscedasticity or homogeneity 






CHAPTER 3. CASE STUDY 
The dataset we used in this study is downloaded from the Gene Expression Omnibus (GEO) 
website (Edgar et al, 2002), which is a part of National Center for Biotechnology Information 
(NCBI). GEO is a public website containing functional genomics data. Array-based and 
sequenced-based data are available.  
GES10645 was used in this study. It is the microarray gene expression of 596 patients with 
prostate cancer using RNA form archival FFPE tissue. In this dataset, there are 201 cases in the 
PSA recurrence group, 200 cases in the systemic disease progression group, and 195 cases in the 
NED group. For each patient, the microarray experiments were conducted on two platforms. 
Totally there are 1028 genes tested. Since there were 4 genes commonly observed in both 
platforms, the expression level of 1024 unique genes were measured in this study. Part of the 
gene expression data is shown in Table 1. The first column of Table 1 is the gene ID reference on 
the microarray platform. The first row of Table 1 is the patient ID. The raw data of the gene 
expression was then collected and normalized using cyclic loess (fastlo) (Ballman et al, 2004). 
The normalized value for the probes was averaged to determine the expression level for the gene. 
The normalized signal intensities of the genes are used to represent the gene expression levels, 







Table 1. Part of Gene Expression of 596 Patients 
 
41 58 67 77 … 480 
EDNRA-Yu-S 2590.818 4475.477 3287.619 3831.178 … 4084.458 
GI_10938013-S 14639.54 16789.44 18280.68 14863.04 … 19507.24 
GI_33457353-S 2249.066 1383.935 2169.257 2045.081 … 1951.291 
GI_4507456-S 3391.451 4358.472 3947.84 4221.654 … 3643.739 
GI_5174574-S 5230.762 14062.15 14035.67 12447.23 … 13644.07 
sarroybu-S 3248.594 1939.159 1291.842 1954.245 … 2272.991 
1557685_at-S 960.0993 710.8403 825.847 701.7497 … 906.67 
1560225_at-S 744.0607 766.0117 688.359 843.965 … 961.933 
1561073_at-S 6091.16 5066.524 5225.532 4069.596 … 6373.923 
213310_at-S 2547.28 2538.185 2095.833 2544.193 … 2622.949 
214174_s_at-S 558.846 545.351 598.894 589.931 … 623.628 
214384_s_at-S 2161.969 2171.385 2066.483 1155.433 … 2858.972 
216584_at-S 3210.32 3485.927 2680.764 2829.81 … 3527.332 
225311_at-S 5116.13 7626.476 7339.999 4772.586 … 9625.634 
228178_s_at-S 777.836 670.6263 690.8893 708.566 … 823.2963 
… … … … … … … 








The phenotypes of patients are shown partly in Table 2. The first column of Table 2 is the 
patient ID. The second column is the phenotypes corresponding to the patient. 












The platforms of the microarray are shown in Table 3. The first column of Table 3 is the 
gene ID reference, which is the same with the first column in Table 1. The second column is the 
GenBank or RefSeq identifier in NCBI. The last column is the gene symbol/name corresponding 








Table 3. Part of the Comparison Table for Microarray Platforms  
ID GB_ACC Symbol 
GI_10092618-S NM_020529.1 NFKBIA 
GI_10337586-S NM_020996.1 FGF6 
GI_10834981-S NM_000599.1 IGFBP5 
GI_10834983-S NM_000600.1 IL6 
GI_10835001-S NM_001175.1 ARHGDIB 
GI_10835048-S NM_001664.1 RHOA 
GI_10835156-S NM_000597.1 IGFBP2 
… … … 
GI_9945438-S NM_002688.2 5-Sep 
 
        The other file used in this research is for the miRNA–target relationships, shown in Table 4, 
which was built by merging five miRNA target datasets: TargetScan (Lewis et al, 2003), 
PciTar4way (Krek et al, 2005), miRBase (Griffiths-Jones et al, 2006), miRanda (John et al, 
2004), and TarBase (Sethupathy et al, 2006). It contains 534 human miRNAs targeting to 
444,558 genes. The first column of Table 4 is the name of miRNAs. The other column is the 








Table 4. Part of miRNA–targets Relationships 















CHAPTER 4. RESULTS 
4.1.  IMRE 
        By using IMRE method, the following ten miRNAs are showed to be the most differently 
expressed miRNAs with a 0.05 FDR threshold: 
Table 5. Results from IMRE Method 
miR-1/206 miR-132/2 miR-376 miR-431 miR-487b 
miR-507 miR-595 miR-636 miR-656 miR-659 
       
      The IMRE method is using the ranks of the gene expression, not the actual expression of the 
genes, as the inputs to find the gene expression difference between targets and non–targets of 
miRNAs. It helps to eliminate the extreme cases in the gene expression data. 
4.2.  ANOVA 
        With all the assumptions satisfied, the ANOVA analysis is used to analyze the data set 









Table 6. Results from ANOVA Method 
miR-128 miR-124.1 miR-34a miR-154 miR-454-3p 
miR-125/351 miR-155 miR-191 miR-130b miR-380-3p 
miR-124.2/506 miR-101 miR-137 miR-342 miR-135 
miR-139 miR-142_3p miR-146b miR-103/107 miR-18a 
miR-1/206 miR-144 miR-184 miR-17_3p miR-129-5p 
miR-10 miR-135a miR-24 miR-33b miR-182* 
miR-204 miR-1 miR-186 miR-20b miR-224 
miR-153 miR-10b miR-329 miR-200b miR-146a 
miR-122a miR-188 miR-132 miR-193b miR-425-5p 
miR-105 miR-10a miR-128a miR-25 miR-185 
miR-181 miR-125a miR-146 miR-145 miR-367 
miR-103 miR-30e-3p miR-126* miR-151 miR-148a 
miR-106b miR-136 miR-141 miR-208 miR-203 
miR-129 miR-147 miR-183 miR-193a miR-210 
miR-127 miR-133a miR-106a miR-130/301 miR-182 
miR-142_5p miR-134 miR-133 miR-624 miR-196b 
miR-100 miR-19a miR-107 miR-143 miR-30b 
miR-130a miR-124a miR-197 miR-138 miR-181a* 
miR-140 miR-500 miR-15a miR-190 miR-150 
 
ANONA is using the actual expression data, but it is difficult to say that one particular 
miRNA did express differently among conditions. All we know is the targets of the miRNA had 
different expression levels in different conditions. Therefore, there might be some false positive 
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cases in the result, which might be part of the reason that we got more miRNAs than the IMRE 
method. 
miR-1/206 is the only miRNA detected by both methods. It is very possible that miR-1/206 




CHAPTER 5. CONCLUSION AND DISCUSSION 
Since the IMRE method is using the differences of the mean scores, which are calculated 
based on the ranks of the gene expression level, between the targets and non-targets of one 
particular miRNA is good at predicting expression differences with/ without this miRNA and 
how it is important in the PSA recurrence in prostate cancer. It might have some biases due to 
using ranks, not actual expression data. On the other hand, the ANOVA method is using the 
actual data, but it doesn’t divide the genes into targets and non-targets gene sets of the miRNAs. 
So it is difficult to determine the expression level difference of one particular miRNA between its 
targets and non–targets. Each method has its own advantages and disadvantages and these two 
methods are complementary. According to the results from IMRE and ANOVA methods, miR-
1/206 was detected by both methods. It is likely that miR-1/206 is important in PSA recurrence 
in prostate cancer. As miR-1 and miR-206 share identical seed sequences, they are commonly 
speculated to target the same gene. 
        Further research would be to figure out the gene targets of miRNA – 1/206 as well as some 
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ArrayInput = "GSE10645.RData" # mRNA-expression input file name. 
ArrayOutput = "Proritized_microRNAs" # Proritized microRNA profile output 
miRNAtargets= "miRNome.txt" 
FDR.T = 0.05  ## Threshold to call a microRNA as significant 
miRNA_profile = "IMRE_res_GSE10645.rdata" # Predicted microRNA profiling generated by 
the "runIMRE" 
 
IMRE <- function(sampleExp, targets, na.last=TRUE)  
{ 
 if (is.na(names(sampleExp)))  stop("Please input sampleExp with probe IDs") 
 allGenes <- names(sampleExp) 
 N <- length(allGenes) 
 nontargets <- allGenes[-which(allGenes %in% targets)] 
 
 # Step 1 (Supporting Figure 2 in the Text S1): Calculation of weighted rank of gene 
expression ----- 
 ## Ranked by score, the lowest to highest. Therefore, the up-regulated genes get the 
higher weighted score 
 rankedExp <- rank(sampleExp) 
 rankscore <- rankedExp*exp(rankedExp/N) 
 
 # Step 2 (Supporting Figure2 in the Text 2): Estimation of regulation for each individual 
microRNAs per a sample using mRNA expression of their putative targets and non putative 
targets ----- 
 ST <- sum(rankscore[targets])/length(targets) 
 SN <- sum(rankscore[nontargets])/length(nontargets) 








 cli2 <- pheno 
 dat <- Expression 
   all<-platform[,3] 
 seeds <- unique(miRTs[,1]) 
 length(seeds)  # old:  534 
 res <- matrix(nrow=length(seeds), ncol=ncol(dat)) 
 rownames(res) <- seeds 
 colnames(res) <- colnames(dat) 
 
 for(i in 1:length(seeds))  
 { 
  targets <- miRTs[which(miRTs[,1]==seeds[i]),2] 
  targetP <- all[which(all %in% targets)] 
    for (x in targetP) { 
    ID<-platform[which(platform[,3]==x),1]   
    } 
    ID<-as.character(ID) 
    for (j in 1:ncol(dat))  
  { 
   res[i,j] <- IMRE(dat[,j],  targets=ID) 
  } 
 } 
 length(which(is.na(res[,1]))) 




  # NED V.S. PSA 
  index<-which(cli2[,2]!="Systemic") 
  phenotype<-cli2[index,] 
 yin <-as.numeric(as.factor(phenotype[,2])) 
  expr<-res[,index] 
 res.S <- twilight.pval(expr, yin, method="t",paired=F, B=1000, filtering=TRUE) 
 save(res.S, file="miRNA_test_result(NEDvsPSA)") 
 
  # NED V.S. Systemic 
  index<-which(cli2[,2]!="PSA") 
  phenotype<-cli2[index,] 
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  yin <-as.numeric(as.factor(phenotype[,2])) 
  expr<-res[,index] 
  res.S <- twilight.pval(expr, yin, method="t",paired=F, B=1000, filtering=TRUE) 
  save(res.S, file="miRNA_test_result(NEDvsSystemic)") 
 
  # PSA V.S. Systemic 
  index<-which(cli2[,2]!="NED") 
  phenotype<-cli2[index,] 
  yin <-as.numeric(as.factor(phenotype[,2])) 
  expr<-res[,index] 
  res.S <- twilight.pval(expr, yin, method="t",paired=F, B=1000, filtering=TRUE) 
  save(res.S, file="miRNA_test_result(PSAvsSystemic)") 
 
  myReport2 <- function(res.S, FDR.T = 0.05, dir="up") 
{ 
 library("stats") 
 resRowLab = rownames(res.S$result) 
 res.T = res.S$result$observed 
 res.P = res.S$result$pval 
 names(res.T) <- names(res.P) <- resRowLab 
 FDR <- p.adjust(res.P, method="fdr") 
 sigFDR <- FDR[which(FDR < FDR.T)] 
 length(sigFDR)  # 73 
 
 if (!is.null(dir)) { 
 if (dir == "up")  dT <- res.T[which(res.T > 0)] else  
    dT <- res.T[which(res.T < 0)] 
 sigFDR <- sigFDR[intersect(names(sigFDR),names(dT))] 
 length(sigFDR)  # 44 
 } 
 sigFDR <- sort(sigFDR) 
 tb<-cbind("Symbol"=names(sigFDR), "target.t"=round(res.T[names(sigFDR)],3), "p-
value"=round(res.P[names(sigFDR)],3),"FDR"=round(FDR[names(sigFDR)],3)) 
 return(list(FDR=FDR, tb=tb,tscore=res.T, pvalue=res.P)) 
} 
 
  load("miRNA_test_result(NEDvsPSA)") 
  finalTable <- myReport2(res.S, FDR.T, "up") 




  load("miRNA_test_result(NEDvsSystemic)") 
  finalTable <- myReport2(res.S, FDR.T, "up") 
  write.csv(finalTable$tb, file=paste(ArrayOutput,"(NEDvsSystemic).csv",sep="")) 
 
  load("miRNA_test_result(PSAvsSystemic)") 
  finalTable <- myReport2(res.S, FDR.T, "up") 
  write.csv(finalTable$tb, file=paste(ArrayOutput,"(PSAvsSystemic).csv",sep="")) 
 
load("miRNA_test_result(NEDvsPSA)") 


















for (i in 1:nrow(Expression)) { 
  fit[[i]]<-lm(Expression[i,]~phenotype) 








difG<-platform[match(row.names(report),platform[,1]),]   # 499 
miRTs<-read.delim("miRNome.txt",sep="\t",header=F,comment.char="") 
difMR<-miRTs[match(difG[,3],miRTs[,2]),]   # 499 
difMR<-difMR[complete.cases(difMR),]   # 424 
unqMR<-difMR[!duplicated(difMR[,1]),]   # 95 
write.table(unqMR[,1],file="micorRNA(ANOVA).txt",row.names=F,col.names=F,quote=F) 
 









while (i <=1192) { 
   
  id<-id+1 
  pat<-pat+1 
   
  if(pat==268403) pat<-pat+1  
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  if(id==12251) id<-id+1 
   
  raw[[i]]$ID<-paste("GSM",pat,sep="") 
   
  sample.ad<-paste(sample1.ad,pat,sep="") 
  source<-readLines(sample.ad) 
  r<-regexec("Case-Control Group: (.*?)<br>",source[286]) 
  raw[[i]]$Phenotype<-regmatches(source[286], r)[[1]][2] 
   
  s<-regexec("Patient (.*?) Core Set",source[271]) 
  raw[[i]]$Patient<-regmatches(source[271],s)[[1]][2] 
   
  data.ad<-paste(data1.ad,pat,"&id=",id,"&db=GeoDb_blob22",sep="") 
  x<-read.table(data.ad,header=F,skip=22,sep="\t",nrows=526,blank.lines.skip=F) 
  x<-subset(x,x[,2]!="NA") 
  names(x)<-c("ID_REF","Value") 
  raw[[i]]$Expression<-x 
  
  i<-i+1 
} 
 
# Phenotype: PSA, NED, Systemic 




for(i in 1:1192) { 
  ID[i]<-raw[[i]]$ID 
  Pheno[i]<-raw[[i]]$Phenotype  
  PatID[i]<-raw[[i]]$Patient 
} 
 
# Combine platforms of the same patient 
join<-list(1192) 
for(i in 1:1191) { 
  join[[i]]<-raw[[i]]$Expression 
  for(j in (i+1):1192){ 
    if (PatID[i]==PatID[j]) join[[i]]<-rbind(join[[i]],raw[[j]]$Expression) 







for (i in 1:1191) { 
  if (nrow(join[[i]])==1028) { 
    expr[[c]]<-join[[i]] 
    index[c]<-i 
    c<-c+1 






# Patient ID 
PatientID<-PatID[index] 
 
# rename column names of expression data 
for (i in 1:596) { 




# Check to see if platforms are in the same order 
for (i in 1:596) { 
  if (expr[[i]][1,1]!="EDNRA-Yu-S") print(i) 
} 
 
for (i in 1:596) { 
  if (expr[[i]][1028,1]!="GI_9945438-S") print(i) 
} 
 
# match merge Expression data 
Expression<-expr[[1]] 
Expression<-as.matrix(Expression) 
for (i in 2:596) { 































for (i in 1:526){ 






# convert NCBI RefSeq ID to Gene Symbol name 
source<-read.table("MatchMinerResult951354746.txt",header=T,skip=20,fill=T) 
source<-source[,c(3,4,5,7)] 








y<-y[-which(y=="line"|y=="-")]  #917 
 
 
 
